Compare Flagstar Bank NA (FLG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Travere Therapeutics Inc. Common Stock — how do they compare? Flagstar Bank NA trades at $11.07 (market cap $4.65B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Flagstar Bank NA and Travere Therapeutics Inc. Common Stock are close in size by market cap, and Flagstar Bank NA pays a 0.36% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 23 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FLG | TVTX | |
|---|---|---|
Market Cap | $4.65B | $4.88B |
Volume | 4,101,836 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $15.36 | $67.52 |
52-Week Low | $10.72 | $26.79 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $15.19B | $5.01B |
Dividend Yield | 0.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.21, down 0.88% with a bearish technical outlook despite recent earnings beats in Q4 2025 and Q1 2026. The stock shows mixed fundamentals with a low P/B ratio of 0.61x but elevated P/E of 373.67x, while profitability metrics remain weak with net income margin at 2.3%. Recent news highlights strategic partnerships and a $250 million share repurchase program, though Q2 2026 earnings missed expectations.
Wall Street maintains a bullish consensus with 60% buy ratings and a $16.81 price target, representing 50% upside potential. Key risks include volatile earnings performance, high valuation multiples, and negative cash flow trends. The company's turnaround efforts and strong capital position provide potential catalysts, but execution risks remain significant.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
